Skip to main content
IMMUTEP LIMITED logo

IMMUTEP LIMITED — Investor Relations & Filings

Ticker · IMM ISIN · AU000000IMM6 LEI · 529900OL6C5CY5P8BH38 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,782 across all filing types
Latest filing 2024-09-18 Director's Dealing
Country AU Australia
Listing ASX IMM

About IMMUTEP LIMITED

https://www.immutep.com

Immutep Limited focuses on the development of novel immunotherapy treatments for cancer and autoimmune diseases, specifically targeting the Lymphocyte Activation Gene-3 (LAG-3) pathway. The company's lead therapeutic candidate is eftilagimod alpha (efti), a first-in-class soluble LAG-3 protein and MHC class II agonist. Efti functions by activating antigen-presenting cells, which in turn triggers a robust T cell response against tumors. It is currently being evaluated in clinical trials for multiple solid tumor indications, including non-small cell lung cancer and head and neck squamous cell carcinoma, frequently in combination with other anti-cancer agents. The pipeline also includes IMP761, an agonist antibody designed to suppress overactive immune responses in autoimmune conditions. The company's technology utilizes the LAG-3 protein's role in immune regulation to create targeted therapeutic interventions.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice - M Voigt 3 pages 186.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares held before and after the change, the nature of the change (on-market trade), and other related information. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It is not an annual report, earnings release, or any other financial report but specifically a director's dealing notice. Therefore, the correct classification is 'DIRS' (Director's Dealing). The document length is under 5,000 characters and contains detailed transaction data, confirming it is the actual notice, not just an announcement or certification.
2024-09-18 English
Data to be presented from Ph II trial in Soft Tissue Sarcoma 2 pages 207.1KB
AGM Information Classification · 90% confidence The document is a company announcement about new clinical trial data to be presented at an upcoming medical conference (Connective Tissue Oncology Society 2024 Annual Meeting). It describes the nature of the data, presentation details, and background on the trial and company. There are no financial statements, regulatory filings, or detailed financial results. The document is an announcement of a presentation at an annual meeting, not the presentation materials themselves. It is not a report, earnings release, or regulatory filing. The content fits best with an Investor Presentation announcement or similar, but since it is announcing new data to be presented at a conference (an annual meeting of a professional society), it aligns most closely with AGM Information (AGM-R) which covers presentations and materials shared during annual general meetings or similar annual conferences. Given the context is a scientific/medical annual meeting presentation announcement, AGM-R is the closest category. Confidence is high as the document clearly states the data will be presented at the CTOS 2024 Annual Meeting and provides presentation details.
2024-09-17 English
New Positive Efficacy Data for Efti in Head and Neck Cancer 4 pages 365.3KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of clinical trial results from Immutep Limited regarding the efficacy and safety of their drug combination in a Phase IIb trial. It includes extensive clinical data, statistical outcomes, and commentary from company executives and medical professionals. The document is not a full annual or interim financial report, nor is it a regulatory filing or certification. It is not a transcript of a call, nor a presentation slide deck, but rather a comprehensive clinical trial results announcement. Given the nature of the content focusing on clinical trial results and efficacy data, it aligns best with a Regulatory Filings (RNS) category, as it is a regulatory announcement of clinical trial results rather than a financial report or investor presentation. The document length (11,482 characters) and detailed data support this classification rather than a brief announcement or a report publication notice.
2024-09-15 English
Becoming a substantial holder 13 pages 2.2MB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 603' and references the Corporations Act 2001 Section 671B, which pertains to the notice of an initial substantial holder. It details the substantial shareholding of JPMorgan Chase & Co. and its affiliates in Immutep Ltd, including voting power, relevant interests, registered holders, consideration paid, and associates. The document includes transaction details and signatures. This type of filing is a notification of a major shareholding change, specifically a substantial holder notice, which aligns with the category 'Major Shareholding Notification' (MRQ). The document is not an annual report, earnings release, or any other financial report but a regulatory disclosure of shareholding interests.
2024-09-11 English
Appendix 4E & 2024 Full Year Statutory Accounts 94 pages 3.0MB
Annual Report Classification · 100% confidence The document is titled 'Preliminary final report' and 'Annual Report 2024' for Immutep Limited, covering the year ended 30 June 2024. It includes detailed financial results, a chairman's letter, review of operations, directors' report, auditor's independence declaration, corporate governance statement, ESG report, and full financial statements including consolidated income statement, balance sheet, cash flows, notes, and auditor's report. The length is substantial (15,000 characters) and contains comprehensive financial and operational information typical of a full annual report. The presence of audited financial statements and detailed corporate disclosures confirms this is the full Annual Report, not just an announcement or summary. Therefore, the correct classification is Annual Report (10-K). FY 2024
2024-08-29 English
Immutep Corporate Presentation 60 pages 5.3MB
Investor Presentation Classification · 95% confidence The document is a detailed corporate presentation from Immutep Limited dated August 2024. It includes extensive information about the company's business, pipeline, clinical programs, financial position, and strategic outlook. The content is structured as a presentation with forward-looking statements, company highlights, product pipeline, clinical data, and commercial opportunity. There is no indication that this is a regulatory filing, earnings release, or annual report. The document is clearly a presentation aimed at investors or stakeholders to provide an update on the company's strategy, clinical progress, and financial health. Therefore, it fits the definition of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2024-08-20 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.